The Clatterbridge Cancer Centre (CCC) has shared an update on its collaboration with The Royal Marsden and Institute of Cancer Research, which has seen the organisations work together to develop “only cancer-specific Biomedical Research Centre” nationwide with funding from the National Institute of Health Research.
The update from CCC shares how the partnership has identified five themes for joint working over the next five years, including in precision diagnostics and cancer evolution; precision therapeutics; advanced technologies for cure; immunotherapeutics; and cancer treatment effects and survivorship. CCC has nominated a lead to plan and map activities and progress in each area.
Professor Kalakonda, the lead for precision therapeutics, highlights how “work has already commenced to establish and progress joint projects within each theme”, adding: “It is a really exciting time to be contributing and participating in clinical research at CCC and we very much look forward to the knowledge exchange that will result from this key collaboration which should ultimately benefit our patients.”
CCC states that the themes have “helped to establish new research partnerships as well as strengthen existing connections between physicians and scientists” across the organisations.
It is expected that participation in cancer-specific BRC activities will support CCC’s “ability to influence and transform” research, trials, treatment and medical technologies, in the hopes of improving patient outcomes regionally and nationally.
Last year, we covered the NIHR’s award of £161 million in funding for 28 clinical research facilities across England, designed to support the delivery of experimental medicine research.
In January, we also looked at the £2.4 million awarded by NIHR to the UK Clinical Research Facility Network to advance research in areas including experimental medicine such as cancer trials.
